Loading clinical trials...

Search of Protein Biomarkers in Order to Achieve a Molecular Classification of Gliomas | Clinical Trials | Clareo Health

COMPLETED

Search of Protein Biomarkers in Order to Achieve a Molecular Classification of Gliomas

NCT02473484•University Hospital, Lille

View on ClinicalTrials.gov

Summary

The aim is to classify high grade glioma by matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI MSI). In order to provide more specific informations for the diagnosis and the prognosis of high grade glioma.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patients with grade III or IV glioma newly diagnosed with histological evidence
•Surgical indication
•Tumor tissue available at biobank of Lille
•Men and women aged ≥ 18 years
•Informed Consent signed by the patient or his legal representative.

Exclusion Criteria

•Antecedents of other cancers except basal cell skin cancer or carcinoma in situ of the uterus cervix
•Previous history of brain radiotherapy
•Anti-tumor systemic treatments (chemotherapy or targeted therapy) prior to surgery of glioma
•Genetic disease that may cause brain tumor, potentially radiation-induced tumor
•History of degenerative neurological disease prior to diagnosis
•contraindication to MRI

Locations (1)

Le Rhun

Lille, France

Key Dates

Start Date

June 24, 2014

Primary Completion Date

October 1, 2017

Completion Date

October 1, 2017

Last Updated

December 22, 2017

Enrollment

ACTUAL participants

Conditions

Glioblastoma

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

NCT06860594

Astrocytoma, IDH-Mutant, Grade 2Recurrent Adult Diffuse Hemispheric Glioma, H3 G34-Mutant+5 more

View study

RECRUITING

Collection of Blood and Urine Samples in Patients Receiving Radiation Therapy for Glioblastoma Multiforme

NCT00083512

Glioblastoma Multiforme

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 22, 2017Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Search of Protein Biomarkers in Order to Achieve a Molecular Classification of Gliomas

Inclusion Criteria

Exclusion Criteria

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

Collection of Blood and Urine Samples in Patients Receiving Radiation Therapy for Glioblastoma Multiforme

Targeted Pediatric High-Grade Glioma Therapy

Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma

EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma

Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma